Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Immatics N.V.    IMTX   NL0015285941

IMMATICS N.V.

(IMTX)
  Report
Delayed Quote. Delayed Nasdaq - 01/26 04:00:00 pm
10.87 USD   -2.69%
01/06IMMATICS N : Corporate Presentation, January 2021
PU
2020Immatics Reports Wider Loss, Higher Revenue in Q3
MT
2020PRESS RELEASE : Immatics Announces Third Quarter -4-
DJ
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immatics N : Factsheet English

11/16/2020 | 04:15am EST

DELIVERING

THE POWER OF T CELLS

TO CANCER PATIENTS

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

THE IMMATICS APPROACH

Unlocking new T cell receptor-based immunotherapies by identifying true targets

Immatics brings together a breadth of technologies matched with deep knowledge of cancer-specific targets and TCRs to achieve the next advance in immunotherapy.

We have inner insight

Immatics has identified and characterized a trove of novel intracellular tumor targets for the development of cancer immunotherapies. We use this knowledge together with our XPRESIDENT® technology to define true targets, distinct molecular barcodes that identify the tumor cell. This gives us a drug discovery advantage that we aim to leverage for our own proprietary pipeline and for our collaborations with world-leading partners.

We pioneer novel therapeutic approaches

TCRs represent a new therapeutic opportunity for engaging T cells against cancer and for attacking the tumor microenvironment. These new treatments are designed to cross cancer's protective barriers and make a therapeutic impact. Immatics continues to innovate using the right TCRs to develop both Adoptive Cell Therapies and novel antibody-like TCR Bispecifics.

We refine and engineer our drug candidates

Through our XCEPTORTM-based process of testing the specificity, affinity and functionality of our TCRs to engage with cancer cells, our drug candidates use the full power of T cells to fight tumor cells.

Our purpose is to make a difference for patients

We have a big goal: overcoming the challenges of fighting cancer and bringing new therapeutic opportunities to cancer patients with high medical need. We will do this with passion and relentless focus to achieve better outcomes for patients.

QUICK FACTS

Established:

2000

Locations:

Tuebingen and Munich, Germany Houston, Texas, USA

Employees:

200 +

Proprietary pipeline:

7 product candidates, thereof 3 in clinical trials

Partnered pipeline:

10 programs partnered with Amgen, Genmab, BMS, GSK

Cancer targets:

More than 200 prioritized cancer targets across multiple cancer indications

IP position:

Over 1,550 secured patents worldwide and over 320 granted patents in the US

NASDAQ Ticker:

IMTX

Shares Outstanding 62,9 million

SENIOR LEADERSHIP

Harpreet Singh, Ph.D.

Chief Executive Officer

Arnd Christ

Chief Financial Officer

Carsten Reinhardt, M.D., Ph.D.

Chief Development Officer

Cedrik Britten, M.D.

Chief Medical Officer

Rainer Kramer, Ph.D.

Chief Business Officer

Steffen Walter, Ph.D.

Chief Technology Officer

Toni Weinschenk, Ph.D.

Chief Innovation Officer

BOARD of DIRECTORS

Peter Chambré (Chairman)

Adam Stone

Christof Hettich, L.L.D.

Eliot Forster, Ph.D.

Heather Maison

Michael Atieh

Paul Carter, FCMA

Contacts:

Anja Heuer

Jordan Silverstein

@immatics

®

Head of Corporate Strategy

Corporate Communications

E-Mail: InvestorRelations@immatics.com

E-Mail: media@immatics.com

Phone: +1 281-810-7545

Phone: +49 89 540415-606

https://www.linkedin.com/company/immatics

www.immatics.com

POTENTIAL OF TCR-BASED IMMUNOTHERAPIES FOR THE TREAMENT OF SOLID CANCERS

FACTS & FIGURES

1 in 6

deaths are related to cancer, making it the second leading cause of death worldwide.

~90%

of all cancers globally are solid cancers where current immunotherapies have shown only limited success.

~300%

more cancer targets are accessible by TCR-based immunotherapies compared to classical antibodies and CAR-T. These immunotherapies are limited to targets on the cell surface which represent only ~25% of all potential tumor targets.

15%

is the forecasted compound annual growth rate (CAGR) for the solid tumor therapeutics market from 2019 - 2024.

PRODUCT PIPELINE

Immatics' fully-owned pipeline consists of Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER™) directed against various targets relevant in a broad range of cancers. Our proprietary XPRESIDENT® and XCEPTOR™ target and TCR technology platforms build the foundation for our broad pipeline with the goal to overcome the current limitations in immuno-oncology and to improve the outcome for patients with solid cancers.

STRATEGIC COLLABORATIONS WITH GLOBAL LEADERS

In addition to our proprietary pipeline, we are developing 10 programs in alliances with global leaders validating our unique technologies and expertise.

Each of the 10 partnered programs may be eligible for

  • >$500 million aggregated milestone payments per program
  • Tiered royalties per program

TWO TREATMENT MODALITIES

We are developing targeted TCR-based immunotherapies with an emphasis on hard-to-treat solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACTengine®) and antibody-like TCR Bispecifics (TCER™). Due to their different mode of action, these modalities are designed to expand the potential therapeutic value for patients across a broad range of tumor types and stages.

Adoptive Cell Therapy (ACT)

Our clinical lead product class ACTengine® is a personalized approach for patients with advanced solid cancers. The patient's own T cells are genetically modified to express a novel proprietary TCR against the cancer target and is then infused back into the patient. ACTengine® programs IMA201, IMA202 and IMA203 are already in clinical studies for a broad range of solid tumor indications, both in the US and in Germany. Our fourth ACTengine® IMA204 program is in pre-clinical stage. It targets the tumor stroma and is designed to disrupt the protective tumor microenvironment. We are further advancing the ACT concept beyond individualized manufacturing with our product class ACTallo® which is being developed to generate "off-the-shelf" cell therapies.

TCR Bispecifics (TCER™)

Our TCER™ molecules are antibody-like"off-the-shelf" biologics engineered to have two binding regions: a TCR which directly recognizes target-positive cancer cells and a T cell recruiter domain which recruits and activates T cells. TCER™ are designed to attract any patient's circulating T cells to bind and come into direct proximity with the cancer to destroy it. Due to their off-the- shelf availability and simple treatment regimen TCER™ have the potential to be cost-effective biologic drug candidates that can be easily distributed.

®

www.immatics.com

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Immatics NV published this content on 16 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 November 2020 09:14:08 UTC


© Publicnow 2020
All news about IMMATICS N.V.
01/06IMMATICS N : Corporate Presentation, January 2021
PU
2020Immatics Reports Wider Loss, Higher Revenue in Q3
MT
2020PRESS RELEASE : Immatics Announces Third Quarter -4-
DJ
2020PRESS RELEASE : Immatics Announces Third Quarter -3-
DJ
2020PRESS RELEASE : Immatics Announces Third Quarter -2-
DJ
2020PRESS RELEASE : Immatics Announces Third Quarter 2020 Financial Results and Busi..
DJ
2020BofA Securities Starts Immatics at Buy With $13 Price Target
MT
2020IMMATICS N : Factsheet English
PU
2020IMMATICS N : ACTolog® IMA101 Phase-1-Data at the 35th Annual SITC conference
PU
2020Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 ..
GL
More news
Financials (USD)
Sales 2020 35,6 M - -
Net income 2020 -275 M - -
Net cash 2020 278 M - -
P/E ratio 2020 -1,73x
Yield 2020 -
Capitalization 684 M 684 M -
EV / Sales 2020 11,4x
EV / Sales 2021 13,5x
Nbr of Employees 230
Free-Float 54,7%
Chart IMMATICS N.V.
Duration : Period :
Immatics N.V. Technical Analysis Chart | IMTX | NL0015285941 | MarketScreener
Technical analysis trends IMMATICS N.V.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 17,40 $
Last Close Price 10,87 $
Spread / Highest target 158%
Spread / Average Target 60,1%
Spread / Lowest Target 19,6%
EPS Revisions
Managers and Directors
NameTitle
Harpreet Singh-Jasuja Chief Executive Officer & Managing Director
Peter Alan Chambré Chairman-Supervisory Board
Arnd Christ Chief Financial Officer
Cedrik M. Britten Chief Medical Officer
Steffen Walter Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
IMMATICS N.V.0.74%684
MODERNA, INC.45.35%58 169
LONZA GROUP AG6.79%50 766
CELLTRION, INC.-10.58%39 697
IQVIA HOLDINGS INC.0.65%35 090
SEAGEN INC.-1.43%32 583